Measurement properties of the SenseWear armband in adults with chronic obstructive pulmonary disease

Kylie Hill,1 Thomas E Dolmage,2 Lynda Woon,1 Roger Goldstein,1 Dina Brooks3

ABSTRACT

Rationale  The SenseWear armband (SAB) is designed to measure energy expenditure (EE). In people with chronic obstructive pulmonary disease (COPD), EE estimated using the SAB (EE_{SAB}) is a popular outcome measure. However, a detailed analysis of the measurement properties of the SAB in COPD is lacking.

Objective  To examine the sensitivity of EE_{SAB}, agreement between EE_{SAB} and EE measured via indirect calorimetry (EE_{IC}), and its repeatability in COPD.

Methods  26 people with COPD (forced expiratory volume in 1 s (FEV1)=49±18% predicted; 15 males) spent 6 min in five standardised tasks that comprised supine, sitting, standing and two walking speeds. A subgroup (n=12) walked using a rollator. Throughout each task, measurements of EE_{SAB} and EE_{IC} were collected. The protocol was repeated on a second day.

Results  EE_{SAB} increased between standing and slow walking (2.4, metabolic equivalents (METs) 95% CI 2.2 to 2.7) as well as slow and fast walking (0.5 METs, 95% CI 0.3 to 0.7). Considering all tasks together, the difference between EE_{SAB} and EE_{IC} was −0.2 METs (p=0.21) with a limit of agreement of 1.3 METs. The difference between days in EE_{SAB} was 0.0 METs with a coefficient of repeatability of 0.4 METs. Rollator use increased the variability in EE_{SAB}, compromising its repeatability and agreement with EE_{IC}.

Conclusions  EE_{SAB} was sensitive to small but important changes. There was fair agreement between EE_{SAB} and EE_{IC}, and measurements of EE_{SAB} were repeatable. These observations suggest that the SAB is useful for the evaluation of EE in patients with COPD who walk without a rollator.

INTRODUCTION

Physical activity confers important health benefits.1 2 The increased energy demands from physical activity require greater substrate delivery, utilisation and product removal from skeletal muscles. Adaptation to such chronic demands conditions the cardiovascular system and may reduce all-cause mortality.3 4 Physical activity is increasingly being used as an outcome measure of treatments for cardiovascular disease (COPD).5 6

Estimating energy expenditure (EE) during daily life is commonly achieved by measuring body movement.7 Inaccuracies associated with self-reports8 have resulted in triaxial accelerometers, which detect movement of the body or limbs and yield accurate measurements of physical activity, emerging as a popular choice.7 8 However, accelerometers cannot detect changes in EE associated with differences in load or efficiency such as from alterations in terrain or gradient, which change energy demands without impacting substantially on body movement. Measurements of EE will be optimised by an approach that does not rely solely on detecting body movement.

Bodymedia (Pittsburgh, Pennsylvania, USA) has developed a lightweight, small metabolic monitor called the SenseWear armband (SAB) which estimates EE (EE_{SAB}) using accelerometer and non-invasive physiological measures.9 Relative to healthy individuals, reduced movement efficiency10 11 and anxiety12 seen in people with COPD may increase oxygen consumption during activity. These differences limit the capacity to generalise measurement properties of the SAB in a healthy population to this patient group. Two studies in COPD have examined the agreement between EE_{SAB} and that derived via indirect calorimetry (EE_{IC}) using a portable gas analysis unit.9 13 Both recruited small samples of subjects with COPD (n<10) and did not report prospective power calculations, or precision of their estimates, thereby limiting confidence in their results.9 13 An assessment was lacking of the sensitivity of the SAB to detect the difference in EE associated with changing from standing to walking at slow speeds.14 Repeatability of measurements over 2 days was not examined. These properties are essential to the planning and interpretation of studies that use the SAB to evaluate EE in people with COPD.

The aim of this study was to examine the sensitivity of EE_{SAB}, defined as its capacity to detect small increases in EE in people with COPD, during tasks that mimicked daily living. Our protocol also allowed examination of: (1) the agreement between EE_{SAB} and EE_{IC} to determine the capacity of the SAB to serve as an indirect calorimeter; (2) the repeatability of EE_{SAB} over two identical test sessions; and (3) the accuracy of the SAB to measure step rate. A secondary aim was to examine the measurement properties of the SAB during rollator-assisted walking as the benefits15 and satisfaction16 with rollators have made them popular among people with COPD. Methods and results pertaining to the secondary aim can be found in the online supplement.

METHODS

Design and study subjects

A cross-sectional observational study was undertaken. Individuals with symptomatic, clinically stable COPD (ratio of postbronchodilator forced expiratory volume in 1 s (FEV1) to forced vital capacity <0.7)17 and a smoking history >10 pack-years were recruited from pulmonary rehabilitation programmes and Respiratory clinics. Individuals were excluded if they: (1) had a co-morbid...
condition thought to compromise mobility such as musculo-
skeletal problems; (2) had a history of mastectomy for right-
sided breast cancer; or (3) were using long-term continuous
oxygen therapy. The study was approved by the Research Ethics
Board at West Park Healthcare Centre. Subjects provided written
informed consent before participation.

Protocol
Subjects attended two sessions, each ~3 h, separated by ≥24 h.
Height and weight were measured. Gender and hand dominance
were recorded. The most recent measurements of resting lung
function and 6 min walk distance (6MWD) were retrieved from
the medical records. During both sessions, subjects undertook
identical tasks in the same sequence while wearing the SAB and
a portable gas analysis system (Cosmed K4b²; COSMED, Rome,
Italy).

Stationary tasks
Subjects spent 6 min in: (1) supine; (2) unsupported sitting; and
(3) upright standing. In supine, a maximum of two pillows were
permitted for comfort.

Active tasks
At the beginning of the first session, before data collection,
subjects were asked to walk 60 m at a speed that they considered
to be ‘slow’ and thereafter at a speed they considered to be ‘faster’,
but one that they could maintain for 6 min. In contrast
to selecting two arbitrary speeds for all subjects, these self-
selected speeds made them relevant to daily life. The time taken
to complete these tasks was recorded and average walking
speeds were calculated. Pilot data indicated that occasionally
subjects were unable to maintain ‘fast’ walking for 6 min.
Therefore, to optimise the likelihood of all subjects completing
the ‘fast’ task, where necessary, the ‘fast’ speed was reduced to
90% of the average speed achieved during the most recent 6 min
walk test. For each subject, the speeds determined at the first
session were used for both test sessions.

During each session, subjects completed two separate 6 min
walking tasks, separated by 15 min, on a 30 m level, enclosed,
temperature-controlled corridor. Speed during the tasks was kept
constant using a methodology adapted from the endurance
shuttle walk test. First, the corridor was marked at 5 m intervals
using orange cones. Then an audio signal of constant periodic
beeps was selected. Each beep corresponding to when the first
investigator needed to pass a cone in order to maintain the
predetermined speed. For example, the audio signal corresponding
to a speed of 50 m/min emitted a beep every 6 s. The subject
followed 2.5 m behind the first investigator and a second inves-
tigator supervised each task to ensure this distance remained
constant. If a subject was unable to maintain the required speed,
the task was terminated. On completion of both walks, dyspnoea
was measured using the Borg category ratio scale (0–10).

Equipment and measurements
SenseWear armband (SAB)
The SAB was worn on the triceps brachii bulk of the right arm.
It estimates EE$_{SAB}$ using measurements from a biaxial acceler-
ometer and sensors that quantify galvanic skin response, heat
flux and skin temperature in a proprietary algorithm (version
6.1). A total of seven SAB devices were used during this study.

Cosmed K4b²
The Cosmed K4b² is a portable telemetric gas analysis unit in which
the face mask, tubing, battery pack and transmitting unit are
lightweight (0.8 kg) and attach via a chest harness. The gas analy-
sers and turbine were calibrated before every use. Measurements
of EE$_{L}$ were estimated from measurements of oxygen uptake where 1
metabolic equivalent (MET) was equal to 3.5 ml/kg/min.

RESULTS
The characteristics of the 26 subjects who consented to partici-
patate are summarised in table 1. One subject (4%) did not return
on the second day of testing due to an acute exacerbation and
one (4%) was unable to tolerate the face mask required for EE$_{IC}$.
On the first day of testing, all subjects completed the stationary
tasks, with 21 (81%) and 17 (65%) completing the slow and fast
walking tasks, respectively. On the second day of testing, 25
(96%) subjects completed the stationary tasks, with 21 (81%) and
16 (61%) completing the slow and fast walking tasks, respectively.
The average speeds selected for the slow and fast
walking tasks were 51.4±11.1 and 65.4±12.4 m/min,
respectively. The slow and fast walking tasks elicited dyspnoea scores equal to 1.4±1.0 and 2.2±1.2, respectively. The average EE for each minute of each task measured using both devices on the first test day are plotted in figure 1A–F. The SAB was well tolerated by all subjects. There was no significant effect of FEV₁ on sensitivity, agreement and repeatability analyses.

Sensitivity
There was no interaction (day×task; F₄₋₇₅=0.83; p=0.51) or effect of day (F₁₋₂₂=0.03; p=0.85) on the difference in EEₛₐᵦ among tasks. Using data collected over both days, there was a significant effect of task on EEₛₐᵦ (F₄₋₈₂=270; p<0.01). The differences between tasks, averaged across both days, are summarised in table 2.

Agreement
There was no interaction (day×task; F₄₋₆₈=0.26; p=0.91), effect of day (F₁₋₂₁=0.03; p=0.87) or task (F₄₋₇₈=1.82; p=0.13) for the difference between EEₛₐᵦ and EEᵢₑᶜ, indicating that the magnitude of difference between EEₛₐᵦ and EEᵢₑᶜ did not differ among days or tasks. The Bland–Altman plot for agreement in EEₛₐᵦ and EEᵢₑᶜ is displayed in figure 2. The overall difference between the devices was 0.2 METs (p=0.21) and the limit of agreement was 1.3 METs. Upper and lower limits of agreement occurred at 1.2 (95% CI 0.7 to 1.7) and −1.5 (−2.0 to −1.0), respectively.

Table 1 Subject characteristics (n=26; 15 males; 2 left-hand dominant)

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mean±SD</th>
<th>Maximum to minimum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>67.4±6.8</td>
<td>84.0 to 48.0</td>
</tr>
<tr>
<td>Height (m)</td>
<td>1.66±0.08</td>
<td>1.80 to 1.47</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>69.0±15.5</td>
<td>99.8 to 39.9</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.8±4.7</td>
<td>33.5 to 14.7</td>
</tr>
<tr>
<td>FEV₁/FVC (%)</td>
<td>39±10</td>
<td>59 to 21</td>
</tr>
<tr>
<td>FEV₁ (litres)*</td>
<td>1.02±0.58</td>
<td>2.51 to 0.57</td>
</tr>
<tr>
<td>FEV₁ (% predicted)*</td>
<td>42.0±15.5</td>
<td>95.0 to 29.0</td>
</tr>
<tr>
<td>RV (litres)</td>
<td>3.88±1.24</td>
<td>6.99 to 2.11</td>
</tr>
<tr>
<td>RV (% predicted)</td>
<td>184.8±59.0</td>
<td>288.0 to 76.0</td>
</tr>
<tr>
<td>6MWD (m)</td>
<td>441±74</td>
<td>634 to 319</td>
</tr>
<tr>
<td>FEV₁ (litres)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV₁ (% predicted)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RV (litres)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>RV (% predicted)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6MWD (m)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Median and IQR as data were not normally distributed. Time between first test session and measurement of lung function and 6MWD was 7.7±5.5 and 2.4±3.0 months, respectively. BMI, body mass index; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; RV, residual volume; 6MWD, 6 minute walk distance.

Figure 1 Profile of energy expenditure (EE) in metabolic equivalents (METs) measured each minute during all tasks on day 1. Data are the mean and SD. Filled circles, SenseWear armband (SAB) data; open circles, indirect calorimetry data.
Repeatability
There was no significant effect of task on the difference in EE measured over the 2 days ($F_{4,22}=0.97, p=0.45$). The Bland–Altman plot for repeatability of EE over the 2 days is displayed in figure 3A. The difference in EE between days was 0.0 METs and the coefficient of repeatability was 0.4 METs. Upper and lower limits occurred at 0.4 (0.3 to 0.6) and −0.5 (−0.6 to −0.3), respectively.

There was no significant effect of task on the difference in EE measured over the 2 days ($F_{4,21}=0.99, p=0.43$). The Bland–Altman plot for repeatability in EE over the 2 days is displayed in figure 3B. The difference in EE between days was 0.0 METs and the coefficient of repeatability was 0.6 METs. Upper and lower limits occurred at 0.6 (0.4 to 0.8) and −0.6 (−0.9 to −0.4), respectively.

Step rate
The average step rate recorded by the SAB was referenced against those calculated via direct observation (figures 4A,B). Using data averaged over the 2 days, step rate measured via SAB was less than that by direct observation at the slow walking speed (77±26 vs 87±9 steps/min; $p=0.04$), but not the faster walking speed (93±22 vs 99±10 steps/min; $p=0.22$).

Table 2 Mean energy expenditure (in metabolic equivalents) measured using the SenseWear armband (SAB) during each task and the difference between tasks

<table>
<thead>
<tr>
<th>Task</th>
<th>Mean, 95% CI</th>
<th>Mean difference, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supine</td>
<td>0.9, 0.8 to 0.9</td>
<td>0.1, 0.0 to 0.2</td>
</tr>
<tr>
<td>Supine to sitting</td>
<td>1.0, 0.9 to 1.1</td>
<td>0.1, −0.1 to 0.2</td>
</tr>
<tr>
<td>Sitting</td>
<td>1.1, 0.9 to 1.2</td>
<td>2.4, 2.2 to 2.7</td>
</tr>
<tr>
<td>Standing</td>
<td>3.5, 3.3 to 3.7</td>
<td>0.5, 0.3 to 0.7</td>
</tr>
<tr>
<td>Standing to slow walking</td>
<td>4.0, 3.7 to 4.2</td>
<td></td>
</tr>
</tbody>
</table>

DISCUSSION
This is the first study to recruit a sample size of sufficient magnitude to examine whether the SAB is able to detect a small increase in EE during common activities of daily living in people with COPD. We have also reported the precision of our estimates. We note that: (1) the EE was sensitive to small but important changes; (2) the limit of agreement in EE and EEIC was 1.3 METs and the difference was not systematic; (3) the coefficient of repeatability for EE was 0.4 METs and the difference was not systematic; and (4) the SAB underestimated step rate at slow walking speeds. In a subgroup, we observed that walking with a rollator increased the variability of EE and compromised its agreement with EEIC.

Significant differences were demonstrated in EE between standing, slow and fast walking. Although earlier work reported that EE increased in response to large increases in walking speed,19 22 our finding is relevant to populations who walk very slowly. The SAB had adequate sensitivity to detect the small increase in average EE (0.5 METs) resulting from a modest increase in average walking speed (14 m/min). The average
increase in distance walked as a consequence of the increased speed (ie, 84 m) is likely to be considered important by individuals with COPD.23 Given the excellent repeatability of the measurement properties of EESAB, a clinician could confidently detect differences resulting from small changes in walking speed of a patient.

The average difference between EESAB and EEIC was small (0.2 METs). Figure 1 reveals that EEIC and EESAB were similar for all tasks. Previous studies in other populations report that, during flat treadmill walking, EESAB was greater than EEIC.19 24 25 The disparity between these results and our data may reflect the faster walking speeds selected during the earlier studies19 25 or differences in efficiency between treadmill and corridor walking. Alternatively, it might reflect differences in the management of the data as we compared EESAB with EEIC only during the steady state. Studies that included data during non-steady state exercise may have underestimated EE24 25.

Our finding of a limit of agreement of 1.5 METs compares favourably with earlier work in healthy individuals and those with cystic fibrosis, reporting limits at 1.5 METs19 and 3.4 METs (assuming mean weight = 70 kg),25 respectively. Our finding of similar measures of EESAB compared with EEIC agrees with one study13 reported that EESAB was lower than EEIC and the magnitude of this difference increased with greater metabolic demands. The disparity between their data and ours may be the result of the older version of software used in the previous study13 or a difference in activities. Our protocol and that used by Langer et al9 were characterised by activities of daily living, while Patel et al13 examined agreement during field-based walking tests and suggested agreement was worse at more intense walking speeds, >82 m/min. As only 2 (8%) subjects in our study selected walking speeds >82 m/min, we do not comment on the agreement between EESAB and EEIC for individuals at these speeds.

Measurements of EESAB were repeatable. One previous study in an obese population reported a strong correlation between EESAB measured at rest over 2 days (r = 0.88; p < 0.001).24 Our data extend this finding by reporting a mean difference in EESAB measured during conditions of daily living over 2 days of 0.0 METs and a coefficient of repeatability of 0.4 METs. Therefore, a difference in average daily EESAB during conditions of daily living of >0.4 METs is needed to be 95% confident that any difference in EESAB is not simply the result of measuring it on a different day. Of interest, EESAB demonstrated less day-to-day variability than EEIC.

The SAB significantly underestimated step rate at slow speeds. Although previously reported,9 our data extend this finding by demonstrating the threshold below which the SAB is unlikely to yield accurate results (ie, speeds <50 m/min).

We present preliminary data to suggest shortcomings of using the SAB in a population who use a rollator to ambulate. Fixation of the upper limit on a rollator is likely to dampen the input from the accelerometer, a contention supported by the large underestimation of step rate during this task. The average EESAB was similar to EEIC, supporting the contention that the SAB algorithm relies more on the physiological sensor data than the accelerometer data in its estimation of EE.13 Nevertheless, the use of a rollator substantially increased the variability in the measurement of EESAB, thereby compromising agreement with EEIC and its repeatability, suggesting that clinically the SAB is unlikely to yield useful measures of EE in rollator users. Given the reduced number of subjects available for these secondary analyses, we emphasise that these data must be interpreted with caution.

Limitations
Although our design enabled us to undertake a detailed examination of the measurement properties of the SAB during walking, the main activity undertaken by people with COPD during daily life,14 we did not evaluate activities such as stair climbing, cycling or upper limb activity, which may contribute to the EE in COPD. Cost and access prevented our undertaking measurements of EE via direct calorimetry or doubly labelled water.7 Although some variability contributing to the limit of agreement may have resulted from measurement error associated with EEIC, portable gas analysis units are widely used to collect the reference measure for determining agreement with EESAB.19 13 19 24 25

CONCLUSION
The SAB is a useful and well-tolerated device in people with COPD. It was sensitive to small increases in EE resulting from increased walking speed. During supine, sitting, standing and walking there was fair agreement between EESAB and EEIC as the limit of agreement was equal to 1.5 METs. Repeatability of
EE_{SAB} was excellent (coefficient of repeatability=0.0 METs) but it underestimated step rate at average walking speeds <50 m/min. Measures of EE_{SAB} collected while walking with a rollator were highly variable and are therefore less likely to be useful.

Acknowledgements We greatly acknowledge the assistance of Clarissa Muere, Dr Vishal Bansal and Sachi O’Hoski with data collection for this study.

Funding Great West Life. DB is supported by a Canada Research Chair and RG by the NSA Chair in Respiratory Rehabilitation Research.

Competing interests None.

Ethics approval This study was conducted with the approval of the West Park Healthcare Centre.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES